Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans

Vaccine

Volumn 33, Issue 31, 2015, Pages 3709-3716

  Schiffer, Jarad M ^a   Chen, Ligong ^b,d   Dalton, Shannon ^b,e   Niemuth, Nancy A ^c   Sabourin, Carol L ^c   Quinn, Conrad P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Atlanta Research and Education Foundation (AREF)   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NONE   (United States)

Author keywords

Animal model; Anthrax; Anthrax Vaccine Adsorbed; AVA; Bacillus anthracis; Biothrax; Clinical trial; Correlates of protection; Non clinical trial

Indexed keywords

ANTHRAX VACCINE; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ANTHRAX; ANTIBODY BLOOD LEVEL; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; ANIMAL MODEL; BIOSTATISTICS; BLOOD; IMMUNIZATION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PRIMATE; PROCEDURES; SURVIVAL;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BIOMARKERS; BIOSTATISTICS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MODELS, ANIMAL; PRIMATES; SURVIVAL ANALYSIS;

EID: 84937631106     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.091     Document Type: Article

References (23)

1. Anthrax Vaccine Adsorbed United States patent US 3208909. September 28, 1965.
2. Turnbull P.C. Anthrax vaccines: past, present and future. Vaccine 1991, 9:533-539. 10.1016/0264-410X(91)90237-Z.
3. Wright J.G., Quinn C.P., Shadomy S., Messonnier N. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2010, 59(RR06):1-30. (PMID: 20651644).
4. Saile E., Quinn C.P. Bacillus anthracis and Anthrax. Bacillus anthracis and anthrax 2010, 269-293. Wiley-Blackwell, New Jersey. N. Bergman (Ed.).
5. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., Ingraham N.R. Field evaluation of a human anthrax vaccine. Am J Public Health 1962, 52:632-645. 10.2105/AJPH.52.4.632.
6. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002, 20:1412-1420. 10.1016/S0264-410X(01)00462-5.
7. Pittman P.R., Fisher D., Quinn X., Schmader T., Barrera-Oro J.G. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity. Vaccine 2013, 31:5009-5014. 10.1016/j.vaccine.2013.08.086.
8. Pittman P.R., Mangiafico J.A., Rossi C.A., Cannon T.L., Gibbs P.H., Parker G.W., et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 2000, 19:213-216. 10.1016/S0264-410X(00)00174-2.
9. Wright J.G., Plikaytis B.D., Rose C.E., Parker S.D., Babcock J., Keitel W., et al. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine 2014, 32:1019-1028. 10.1016/j.vaccine.2013.10.039.
10. Quinn C.P., Sabourin C.L., Niemuth N.A., Li H., Semenova V.A., Rudge T.L., et al. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin Vaccine Immunol 2012, 19:1730-1745. 10.1128/CVI. 00324-12.
11. Chen L., Schiffer J.M., Dalton S., Sabourin C.L., Niemuth N.A., Madigan D., et al. Comprehensive analysis and selection of anthrax vaccine immune correlates of protection in rhesus macaques. Clin Vaccine Immunol 2014, 21:1512-1520. 10.1128/CVI.00469-14.
12. Gronvall G.K., Trent D., Borio L., Brey R., Nagao L. The FDA animal efficacy rule and biodefense. Nat Biotechnol 2007, 25:1084-1087. 10.1038/nbt1007-1084.
13. Fay M.P., Follmann D.A., Lynn F., Schiffer J.M., Stark G.V., Kohberger R., et al. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med 2012, 4:151ra126. 10.1126/scitranslmed.3004073.
14. Kohberger R.C., Jemiolo D., Noriega F. Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine 2008, 26:3516-3521. 10.1016/j.vaccine.2008.04.016.
15. Efron B., Tibshirani J. An introduction to the Bootstrap 1993, Chapman and Hall, New York.
16. Semenova V.A., Schiffer J., Steward-Clark E., Soroka S., Schmidt D.S., Brawner M.M., et al. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-Pa IgG. J Immunol Methods 2012, 376:97-107. 10.1016/j.jim.2011.12.002.
17. Li H., Soroka S.D., Taylor T.H., Stamey K.L., Stinson K.W., Freeman A.E., et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008, 333:89-106. 10.1016/j.jim.2008.01.007.
18. Brachman P.S., Plotkin S.A., Bumford F.H., Atchison M.M. An epidemic of inhalation anthrax: the first in the twentieth century. Am J Hyg 1960, 72:6-23. (PMID: 13803672).
19. Dahlgren C.M., Buchanan L.M., Decker H.M., Freed S.W., Phillips C.R., Brachman P.S. Bacillus anthracis aerosol in goat hair processing mills. Am J Hyg 1960, 72:2-31. (PMID: 138720).
20. Toth D.J.A., Gundlapalli A.V., Schell W.A., Bulmahn K., Walton T.E., Woods C.W., et al. Quantitative models of the dose response and time course of inhalational anthrax in humans. PLOS Pathog 2013, 9(8):1003555. doi:10.1371/journal.ppat.1003555.
21. Masuet Aumatell C., Ramon Torrell J.M., Zuckerman J.N. Review of oral cholera vaccines: efficacy in young children. Infect Drug Resist 2011, 4:155-160. 10.2147/IDR.S10339.
22. Li R.C., Huang T., Li Y., Luo D., Tao J., Fu B., et al. Human Rotavirus Vaccine (Rix4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Hum Vaccin Immunother 2013, 10:11-18. 10.4161/hv.26319.
23. MacNeil J.R., Cohn A.C., Zell E.R., Schmink S., Miller E., Clark T., et al. Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011, 30:451-455. 10.1097/INF.0b013e31820a8b3c.